Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.
about
Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Nimotuzumab abrogates acquired ...... aling and cellular DNA repair.
@ast
Nimotuzumab abrogates acquired ...... aling and cellular DNA repair.
@en
type
label
Nimotuzumab abrogates acquired ...... aling and cellular DNA repair.
@ast
Nimotuzumab abrogates acquired ...... aling and cellular DNA repair.
@en
prefLabel
Nimotuzumab abrogates acquired ...... aling and cellular DNA repair.
@ast
Nimotuzumab abrogates acquired ...... aling and cellular DNA repair.
@en
P2093
P2860
P356
P1476
Nimotuzumab abrogates acquired ...... aling and cellular DNA repair.
@en
P2093
Bengxin Gu
Huaping Gao
Qinghua Dong
Tingting Jiang
Weifang Yang
Wenhong Xu
Xiaonan Sun
P2860
P304
P356
10.2147/OTT.S76958
P407
P577
2015-02-25T00:00:00Z